Cost-effectiveness analysis of NVX-CoV2373 COVID-19 vaccination for elderly people in Japan

This publication has 20 references indexed in Scilit:

• Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
  Vaccine, 2023
• Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial
  Vaccine, 2023
• Comparison of the clinical characteristics and outcomes of Japanese patients with COVID-19 treated in primary, secondary, and tertiary care facilities
  Journal of Infection and Chemotherapy, 2022
• Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
  The Lancet Infectious Diseases, 2022
• Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States
  International Journal of Infectious Diseases, 2022
• Cost Utility of Vaccination Against COVID-19 in Brazil
  Value in Health Regional Issues, 2022
• Legal and regulatory processes for Japan’s COVID-19 immunization program
  Vaccine, 2021
• Japanese Population Norms of EQ-5D-5L and Health Utilities Index Mark 3: Disutility Catalog by Disease and Symptom in Community Settings
  Value in Health, 2021
• The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization
  Vaccine, 2021
• International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?
  Health Economics, 2009